Anesketin 100 mg/ml Solution for Injection

Main information

  • Trade name:
  • Anesketin 100 mg/ml Solution for Injection
  • Pharmaceutical form:
  • Solution for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Anesketin 100 mg/ml Solution for Injection
    Spain
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • ketamine
  • Therapeutic area:
  • Cats, Dogs, Horses, Other

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0459/001
  • Authorization date:
  • 20-03-2013
  • EU code:
  • UK/V/0459/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:July2013

AN.02141/2011

Page1of13

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

ANESKETIN100mg/mlsolutionforinjectionfordogs,catsandhorses

Belgium:

NIMATEK100mg/mlsolutionforinjectionfordogs,catsandhorses

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Activesubstance:

Ketamine 100mg/ml

(correspondingtoketaminehydrochloride115.4mg/ml)

Excipient(s):

Chlorocresol 1mg/ml

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Solutionforinjection.

Clear,colourlessliquidfreefromvisibleevidenceofcontamination

4. CLINICALPARTICULARS

4.1Targetspecies

Dog,catandhorse.

4.2Indicationsforuse,specifyingthetargetspecies

Theproductmaybeusedasasoleagentforrestraintandminorsurgicalprocedures

wheremusclerelaxationisnotrequiredinthedomesticcat.

Theproductmayalsobeusedtoinduceanaesthesia:

a)inconjunctionwithbutorphanolandmedetomidineinthedogandcat,

b)inconjunctionwithxylazineinthedog,catandhorse,

c)inconjunctionwithdetomidineinthehorse,

d)inconjunctionwithromifidineinthehorse.

4.3Contraindications

Donotuseinanimalswithhepaticorrenalfailure.

Donotuseketamineasasoleagentinthehorseorthedog.

Donotuseinanimalswithseverecardiacde-compensation,apparenthighblood

pressureorglaucoma.

Donotuseinanimalswitheclampsiaorpre-eclampsia.

Donotuseincasesofhypersensitivitytotheactivesubstanceoranyoftheexcipients.

Issued:July2013

AN.02141/2011

Page2of13

4.4Specialwarningsforeachtargetspecies

Forverypainfulandmajorsurgicalinterventions,aswellasformaintenanceof

anaesthesia,acombinationwithinjectableorinhalationanaestheticsisnecessary.As

musclerelaxationrequiredforsurgicalprocedurescannotbeachievedwithketamine

alone,additionalmuscle-relaxantsshouldbeusedconcomitantly.Forimprovementof

anaesthesiaorprolongationofeffectketaminecanbecombinedwith α

-receptor-

agonists,anaesthetics,neuroleptanalgesics,tranquilizersandinhalationalanaesthetic

agents.Itshouldbenotedthattime-to-full-effectmaybeprolongedwhenusingthe

subcutaneousadministrationrouteincat.

4.5Specialprecautionsforuse

Specialprecautionsforuseinanimals:

Asmallproportionofanimalshavebeenreportedtobeunresponsivetoketamineasan

anaestheticagentatnormaldosages.Useofpremedicantsshouldbefollowedbya

suitablereductionindosage.

Inductionandrecoveryshouldbeallowedtooccurinquietandcalmsurroundings.

Asforallanaestheticsanimalsshouldbefastedfor12hoursbeforeketamine

anaesthesia.

Atropinepremedicationmayreducesalivationincats.

Musculartwitchingandmildtonicconvulsionshavebeenreportedinthecatat

recommendeddoserates.Thesesubsidespontaneouslybutmaybepreventedbyuse

ofacepromazineorxylazinepremedication,orcontrolledbyuseofacepromazineor

ultra-shortactingbarbituratesinlowdoses.

Inthecatanddog,theeyesremainopenandthepupilsdilated.Theeyesmaybe

protectedbycoveringwithadampgauzeswaborusingappropriateointments.

Ketaminemayexhibitpro-convulsantandanti-convulsantproperties,andtherefore

shouldbeusedwithcareinpatientswithseizuredisorders.

Ketaminemayincreaseintracranialpressureandtherefore,maynotbesuitablefor

patientswithcerebrovascularinsults.

Whenusedincombinationwithotherproducts,consultthecontraindicationsand

warningsthatappearontherelevantdatasheets.

Specialprecautionstobetakenbythepersonadministeringtheveterinarymedicinal

producttoanimals:

Thisisapotentdrug.Particularcareshouldbetakentoavoidaccidentalself-

administration.

Peoplewithknownhypersensitivitytoketamineoranyoftheexcipientsshouldavoid

contactwiththeveterinarymedicinalproduct.

Avoidcontactwiththeskinandeyes.Washanysplashesfromskinandeyes

immediatelywithlargeamountsofwater.

Adverseeffectsonthefoetuscannotbeexcluded.Pregnantwomenshouldavoid

handlingtheproduct.

Incaseofaccidentalself-injectionorifsymptomsoccurafterocular/oralcontact,seek

medicaladviceimmediatelyandshowthepackageleafletorthelabeltothephysician,

butDONOTDRIVE.

Advicetodoctors:

Issued:July2013

AN.02141/2011

Page3of13

Donotleavepatientunattended.Maintainairwaysandgivesymptomaticandsupportive

treatment.

4.6Adversereactions(frequencyandseriousness)

Ketaminemaycausesalivationincats.

Ketaminecausesanincreasedtonusofskeletalmuscles.Musculartwitchingandmild

tonicconvulsionshavebeenreportedinthecatatrecommendeddoserates.

Ketaminecausesadose-relatedrespiratorydepression,whichmayleadtorespiratory

arrestparticularlyincats.Combinationwithrespiratorydepressantproductsmay

increasethisrespiratoryeffect.

Ketamineincreasestheheartrateandincreasesarterialbloodpressurewithconcurrent

increasedbleedingtendency.

Incatsanddogseyesremainopenedwithmydriasisandnystagmus.

Emergencereactions-ataxia,hypersensitivitytostimuli,excitation –mayoccurduring

recovery

Theremaybesomepainonintramuscularinjection.

4.7 Useduringpregnancy,lactationorlay

Ketaminepassesthebloodplacentabarrierverywell,enteringthefoetalblood

circulationbywhich75to100%ofthematernalbloodlevelscanbereached;this

anesthetizespartiallythepupsatbirthdeliveredbycaesareansection.

Theuseoftheproducthasnotbeenassessedduringpregnancyandlactation.Useonly

accordinglytothebenefit/riskassessmentbytheresponsibleveterinarian.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Careshouldbetakenwhenusingketamine-halothanecombinationssincehalf-lifeof

ketamineisprolonged.Neuroleptanalgesics,tranquilizersandchloramphenicol

potentiateketamineanaesthesia.Barbituratesandopiatescanprolongtherecovery

period.Ketaminehasbeenreportedtoenhancetheoccurrenceoftachycardiaand

hypertensionwhenusedinhumanpatientsreceivingthyroidhormones.

4.9Amountstobeadministeredandadministrationroute

Forusebyintramuscular,subcutaneousorintravenousinjection.

Itshouldbenotedthatdosagesandroutesofadministrationvarywidelybetween

species.Furthermore,theeffectofketaminemayshowlargeinter-individualdifferences

andtherefore,individualdosageaccommodationisrecommended.

DOG:

Xylazine/ketamine:

Administerxylazineatadoserateof1mg/kgbyintramuscularinjection(corresponding

to0.5ml/10kgbodyweightofxylazine2%solution).Immediatelyadministerketamine

atadoserateof15mg/kgbyintramuscularinjection(correspondingto1.5ml/10kg

bodyweight).

Issued:July2013

AN.02141/2011

Page4of13

Dogsbecomerecumbentinapproximately3minutesandlosetheirpedalreflexin

approximately7minutes.Durationofanaesthesiaisapproximately24minutes,the

pedalreflexreturningabout30minutesfollowingadministrationoftheketamine

injection.

Table1:XylazineandKetamine100mg/mlcanineanaesthesia(IM)

Weightofdogs(kg) 1 3 5 10 15 20 25 30 40

Xylazine2%dose

(ml)* 0.050.150.250.500.751.001.251.502.00

Ketamine100mg/ml

dose

(ml)** 0.150.450.751.502.253.003.754.506.00

*basedonadoserateof1mgxylazine/kgbodyweight

**basedonadoserateof15mgketamine/kgbodyweight

Medetomidine/ketamine:

Administermedetomidineatadoserateof40µg/kg(correspondingto0.40ml/10kg

bodyweightofmedetomidine1mg/mlsolution)andketamineat5.0-7.5mg/kg

(correspondingto0.5-0.75ml/10kgbodyweight),dependingondurationofanaesthesia

required,byintramuscularinjection.

Lossofpedalreflexoccursapproximately11minutesfollowinginjectionat5mg

ketamine/kgand7minutesfollowinginjectionat7.5mgketamine/kg.Durationof

anaesthesiaisapproximately30and50minutesrespectively.

ItisNOTadvisabletoreversethiscombinationinthedogwithatipamezole.

Table2:Medetomidineandketaminecanineanaesthesia(IM):Dosagechartfor

5mgketamine/kg(durationofanaesthesiaapproximately30min)

Weightofdogs(kg) 1 3 5 10 15 20 25 30 40

Medetomidine(1

mg/ml)dose(ml)* 0.040.120.200.400.600.801.001.201.60

Ketamine(100mg/ml)

dose

(ml)** 0.050.150.250.500.751.001.251.502.00

*basedonadoserateof40µgmedetomidine/kgbodyweight

**basedonadoserateof5mgketamine/kgbodyweight

Table3:Medetomidineandketaminecanineanaesthesia(IM):Dosagechartfor

7.5mgketamine/kg(durationofanaesthesiaapproximately50min)

Weightofdogs(kg) 1 3 5 10 15 20 25 30 40

Medetomidine(1

mg/ml)dose(ml)* 0.040.120.200.400.600.801.001.201.60

Ketamine(100mg/ml)

dose

(ml)** 0.080.230.380.751.131.501.882.253.00

*basedonadoserateof40µgmedetomidine/kgbodyweight

**basedonadoserateof7.5mgketamine/kgbodyweight

Butorphanol/medetomidine/ketamine:

Administerbutorphanolat0.1mg/kgandmedetomidineat25µg/kgbyintramuscular

injection.

Issued:July2013

AN.02141/2011

Page5of13

Dogsbecomerecumbentinapproximately6minutesandlosetheirpedalreflexin

approximately14minutes.

Ketamineinjectionshouldbeadministered15minutesfollowingthefirstinjectionata

doserateof5mg/kgbyintramuscularinjection(correspondingto0.5ml/10kg

bodyweight).

Thepedalreflexreturnsapproximately53minutesfollowingadministrationofthe

Ketamine100mg/mlinjection.Sternalrecumbencyisattainedapproximately35

minuteslaterfollowedbystandingafurther36minuteslater.

ItisNOTadvisabletoreversethiscombinationinthedogwithatipamezole.

Table4:Butorphanol,medetomidineandketaminecanineanaesthesia(IM)

Weightofdogs(kg) 1 3 5 10 15 20 25 30 40

Butorphanol(10mg/ml)

dose(ml)* 0.010.030.050.100.150.200.250.300.40

Medetomidine(1

mg/ml)dose(ml)** 0.030.080.130.250.380.500.630.751.00

Administerbutorphanolandmedetomidinebyintramuscularinjectionatthe

abovedoserates

Wait15minutesbeforeadministeringketaminebyintramuscularinjectionat

thedoseratesbelow

Ketamine(100mg/ml)

dose(ml)*** 0.050.150.250.500.751.001.251.502.00

* basedonadoserateof0.1mgbutorphanol/kgbodyweight

**basedonadoserateof25µgmedetomidine/kgbodyweight

***basedonadoserateof5mgketamine/kgbodyweight

CAT:

Ketamineasasoleagent:

Mono-anaestheticuseofketamineispossible,buttoavoidundesiredpsycomotoric

effectscombinedanaesthesiaisrecommended.Ketamineonitsownmaybeusedby

intravenousorsubcutaneousinjection,butintramuscularinjectionistherecommended

route.Thedoseis11-33mgketamine/kgdependingonthedegreeofrestraintor

surgicalinterferencethatisintended.Thefollowingdosagesareindicatedasaguide

butmayneedtobeadjusteddependingonthephysicalconditionofthepatientandthe

usageofsedativesandpremedicants.

Dose(mg/kg) Clinicalprocedures

11(0.11ml/kg)

22-33(0.22-0.33ml/kg) Minorrestraint

Minorsurgeryandrestraintoffractious

cats

Durationofketamineanaesthesiais20-40minutesandrecoverytakesplaceoveran1-

4hourperiod.

Formajorsurgery,ketamineshouldbeusedinconjunctionwithsupplementalsedatives

oranaesthetics.Dosagevariesfrom1.25-22mg/kg(0.06-1.1ml/5kg)dependingon

thecombinationandrouteofadministrationused.

Vomitingisunlikelytooccurwhenketamineisusedalone,however,catsshouldbe

starvedforseveralhourspriortoanaesthesiawherepossible.

Ketaminesupplementarycombinationsinthecat:

Issued:July2013

AN.02141/2011

Page6of13

Atropinepremedicationisgenerallyrecommendedat0.05mg/kgtoreducesalivation.

Inaddition,acepromazine(0.2%solution)atadoserateof0.11mg/kg(corresponding

to0.28ml/5kgbodyweight)canbeadministeredbyintramuscularinjection,as

premedicant.Endotrachealintubationcanbeachievedduringketamineanaesthesia.

Inhalationanaesthesiamaybemaintainedbysuitablecombinationsofmethoxyflurane,

halothane,nitrousoxideandoxygen.

Xylazine/ketamine:

Administerxylazineatadoserateof1.1mg/kg(correspondingto0.28ml/5kg

bodyweightofxylazine2%solution)andatropineatadoserateof0.03mg/kg

(correspondingto0.25ml/5kgbodyweightofatropine0.06%solution)byintramuscular

injection.Wait20minutesandthenadministerketamineatadoserateof22mg/kg

(correspondingto1.1ml/5kgbodyweight)byintramuscularinjection.

Xylazinemayinducevomitingupto20minutesafteradministration.Onsetof

anaesthesiaafterintramuscularinjectionofketaminetakessome3-6minutes.

Axylazine/ketaminecombinationproducesadeeperanaesthesiawithmore

pronouncedrespiratoryandcardiaceffectsandalongerrecoveryperiodthan

acepromazine/ketaminecombinations.

Table5:Xylazineandketaminefelineanaesthesia(IM)

Weightofcat(kg) 1.5 2 2.5 3 3.5 4 4.5 5

Xylazine2%dose(ml)* 0.080.110.140.170.190.220.250.28

Atropine(600µg/ml)

dose(ml)** 0.080.100.130.150.180.200.230.25

Wait20minutes

Ketamine(100mg/ml)

dose(ml)*** 0.330.440.550.660.770.880.991.10

* basedonadoserateof1.1mgxylazine/kgbodyweight

**basedonadoserateof0.03mgatropine/kgbodyweight

***basedonadoserateof22mgketamine/kgbodyweight

Medetomidine/ketamine:

Intramuscular:

Administermedetomidineatadoserateof80µg/kgbyintramuscularinjection.This

shouldbefollowedimmediatelybytheintramuscularinjectionofketamineadoserateof

2.5-7.5mg/kg(correspondingto0.12-0.38ml/5kgbodyweight).

Onsetofanaesthesiais3-4minutes.Thedurationofsurgicalanaesthesiavaries

between30-60minutesandisrelatedtothedoseofketamineused.Ifrequired,

anaesthesiamaybeprolongedwithhalothaneandoxygenwithorwithoutnitrousoxide.

Table6:Medetomidineandketaminefelineanaesthesia(IM)

Weightofcat(kg) 1.5 2 2.5 3 3.5 4 4.5 5

Medetomidine(1

mg/ml)dose(ml)* 0.120.160.200.240.280.320.360.40

Ketamine(100mg/ml)

dose

(ml)** 0.080.100.130.150.180.200.230.25

*basedonadoserateof80µgmedetomidine/kgbodyweight

**basedonadoserateof5mgketamine/kgbodyweight

Issued:July2013

AN.02141/2011

Page7of13

Intravenous:

Medetomidineandketaminemaybeadministeredbyintravenousinjectionatthe

followingdoserates:40µgmedetomidine/kgand1.25mgketamine/kg.

Clinicalexperiencehasshownthatwhenketamineandmedetomidinehavebeenused

intravenouslyincatsandtheneedforanaesthesiahaspassed,administrationof100µg

atipamezole/kgbyintramuscularinjectionresultsinrecoverytosternalrecumbencyin

approximately10minutesandtostandinginapproximately14minutes.

Table7:Medetomidineandketaminefelineanaesthesia(IV)

Weightofcat(kg) 1.5 2 2.5 3 3.5 4 4.5 5

Medetomidine(1

mg/ml)dose(ml)* 0.060.080.100.120.140.160.180.20

Ketamine(100mg/ml)

dose

(ml)** 0.020.030.030.040.050.050.060.06

*basedonadoserateof40µgmedetomidine/kgbodyweight

**basedonadoserateof1.25mgketamine/kgbodyweight

Atropineisnotnormallynecessarywhenusingamedetomidine/ketaminecombination.

Useofeitherinsulinsyringesor1mlgraduatedsyringesisrecommendedtoensure

accuratedosing.

Butorphanol/medetomidine/ketamine:

Intramuscular:

Administerbutorphanolatadoserateof0.4mg/kg,medetomidineatadoserateof80

µg/kgandketamineatadoserateof5mg/kg(correspondingto0.25ml/5kg

bodyweight)byintramuscularinjection.

Catsbecomerecumbentin2-3minutesfollowinginjection.Lossofpedalreflexoccurs3

minutespostinjection.At45minutespostinduction,reversalwith200µg

atipamezole/kgresultsinreturnofpedalreflex2minuteslater,sternalrecumbency6

minuteslaterandstanding31minuteslater.

Table8:Butorphanol,medetomidineandketaminefelineanaesthesia(IM)

Weightofcat(kg) 1.5 2 2.5 3 3.5 4 4.5 5

Butorphanol(10mg/ml)

dose(ml)* 0.060.080.100.120.140.160.180.20

Medetomidine(1

mg/ml)dose(ml)** 0.120.160.200.240.280.320.360.40

Ketamine(100mg/ml)

dose

(ml)*** 0.080.100.130.150.180.200.230.25

* basedonadoserateof0.4mgbutorphanol/kgbodyweight

**basedonadoserateof80µgmedetomidine/kgbodyweight

***basedonadoserateof5mgketamine/kgbodyweight

Intravenous:

Administerbutorphanolatadoserateof0.1mg/kg,medetomidineatadoserateof40

µg/kgandketamine,dependingondepthofanaesthesiarequired,atadoserateof

1.25-2.5mg/kg(correspondingto0.06-0.13ml/5kgbodyweight)byintravenous

injection.

Issued:July2013

AN.02141/2011

Page8of13

Approximatetimescaleswhenusingthetriplecombinationintravenously:

Ketamine

dose

(mg/kg)* Timeto

recumbency Timetoloss

ofpedal

reflex Timeto

returnof

pedalreflex Timeto

sternal

recumbency Timeto

standing

1.25 32sec 62sec 26min 54min 74min

2.50 22sec 39sec 28min 62min 83min

*inconjunctionwithbutorphanolat0.1mg/kgandmedetomidineat40µg/kg

Clinicalexperiencehasshownthatreversal,atanystage,with100µgatipamezole/kg

resultsinreturnofthepedalreflex4minuteslater,sternalrecumbency7minuteslater

andstanding18minuteslater.

Table9:Butorphanol,medetomidineandketaminefelineanaesthesia(IV):

Dosagechartfor2.5mg/kgketamine(durationofanaesthesiaapproximately28

minutes)

Weightofcat(kg) 1.5 2 2.5 3 3.5 4 4.5 5

Butorphanol(10mg/ml)

dose(ml)* 0.020.020.030.030.040.040.050.05

Medetomidine(1

mg/ml)dose(ml)** 0.060.080.100.120.140.160.180.20

Ketamine(100mg/ml)

dose

(ml)*** 0.040.050.060.080.090.100.110.13

* basedonadoserateof0.1mgbutorphanol/kgbodyweight

**basedonadoserateof40µgmedetomidine/kgbodyweight

***basedonadoserateof2.5mgketamine/kgbodyweight

HORSE:

Fortheproductionofshort-termanaesthesiasuitableforminorsurgicalinterferencesor

forinductionpriortoinhalationanaesthesia.Whenromifidineordetomidineareusedas

thepremedicant,anaesthesiamayalsobemaintainedwitha‘top-up’combinationof

eitherromifidineandKetamine100mg/mlordetomidineandketamineatregular8-10

minuteintervals.Ketamineshouldneverbeusedasasoleanaestheticagent.

Itisgenerallyacceptedasgoodanaestheticpracticetostarveanimalsforaperiodprior

toanaesthesiawherepossible.

Toachievethebestresults,itisimportantthehorsesarenotstressedbeforethe

anaesthetic.Itisequallyimportantthatthewholeprocedure,frominductiontorecovery,

shouldtakeplaceinquietandcalmsurroundings.

Forhorsesthatarestressedbeforetheprocedure,theuseof0.03mg/kgacepromazine

45minutespriortoadministrationofeitherdetomidineorromifidinefacilitateshandling

andplacementofanintravenouscatheter.

Ifthehorsefailstobecomesedatedfollowingtheinjectionofeitherxylazine,detomidine

orromifidine,thenketamineshouldnotbeinjectedandtheanaestheticprocedure

shouldbeabandoned.Thesituationshouldbeassessedtoestablishwhythehorse

failedtorespond,andthentheenvironmentand/orthedrugsshouldbeadjustedas

necessary,beforetryingagainthefollowingday.

Whenusingatotalintravenoustechniqueandforsafeandeffectiveuseofatop-up

regime,theuseofanintravenouscatheterisstronglyadvised.

Duringcastrationithasbeennotedthattheuseof10mllidocainedividedbetweenthe

testicleseliminatesthepossibleresponsetoligationofthetesticularcordand

minimisesthenumberoftop-upsrequired.

Issued:July2013

AN.02141/2011

Page9of13

Xylazine/ketamine:

Xylazineshouldbeadministeredbyslowintravenousinjectionatadoserateof1.1

mg/kg(correspondingto1.1ml/100kgbodyweightofxylazine10%solution).Thehorse

shouldappearsedatedby2minutespostinjection.Injectionofketamineshouldbe

administeredatthisstage.Itisrecommendednottodelaytheketamineinjectionlonger

than5minutesafterxylazineadministration.Ketamineshouldbeadministeredasan

intravenousbolusatadoserateof2.2mg/kg(correspondingto2.2ml/100kg

bodyweight).

Inductionandrecumbencytakesome1-2minutes.Musclejerkingmayoccurinthefirst

minutes,butthisusuallysubsides.

Anaesthesiaisvariableinduration,lastingbetween10-30minutes,butusuallylessthan

20minutes.Horsesinvariablystand25-45minutesafterinduction.Recoveryisgenerally

quiet,butmayoccursuddenly.Itisimportantthereforethatshortdurationinterferences

onlyareattempted,orarrangementstoprolonganaesthesiaaremade.Forlonger

periodsofanaesthesia,intubationandmaintenancebyinhalationanaesthesiacanbe

used.

Table10:Xylazineandketamineequineanaesthesia(IV)

Weightofhorse(kg) 50 100 150 200 250 300 400 500 600

Xylazine10%dose

(ml)* 0.601.101.702.202.803.304.40 5.50 6.60

Wait2minutes

Ketamine(100mg/ml)

dose(ml)** 1.102.203.304.405.506.608.8011.0013.20

*basedonadoserateof1.1mgxylazine/kgbodyweight

**basedonadoserateof2.2mgketamine/kgbodyweight

Detomidine/ketamine:

Detomidineshouldbeadministeredbyintravenousinjectionatadoserateof20µg/kg.

Thehorseshouldappearsedatedbyfiveminutespostinjection.Atthisstageketamine

shouldbeadministeredatadoserateof2.2mg/kg(correspondingto2.2ml/100kg

bodyweight)asanintravenousbolus.

Onsetofanaesthesiaisgradual;mosthorsestakeapproximately1minutetobecome

recumbent.Large,fithorsesmaytakeupto3minutesforrecumbency.Anaesthesia

continuestodeepenforafurther1-2minutesandduringthistimethehorseshouldbe

leftquietly.Horsesregainsternalrecumbencyapproximately20minutespostketamine

injectiongivingasurgicalanaesthesiadurationof10-15minutes.

Maintenanceofsurgicalanaesthesia:

Shoulditbecomenecessarytoprolonganaesthesia,eitherofthefollowingregimesmay

beused:

a)Thiopentalsodium

Thiopentalsodiummaybeadministeredintravenouslyinbolusesof1mg/kgas

required.Totaldosesof5mg/kg(five1mg/kgincrements)havebeengiven.Total

dosesgreaterthanthismayreducethequalityofrecovery.Thiopentalsodiumcanalso

beadministeredinincrementsifsufficientdepthofanaesthesiaisnotachieved.The

horsemaybeataxicifencouragedtostandprematurelyandsoshouldbelefttostandin

itsowntime.

b)Detomidine/ketamine

Issued:July2013

AN.02141/2011

Page10of13

Administer10µgdetomidine/kg,i.e.½theinitialpremedicationdosebyintravenous

injection,followedimmediatelyby1.1mgketamine/kg,i.e.½theinitialinductiondose

byintravenousinjection.Thiswillprovideapproximately10minutesadditionalsurgical

anaesthesia,whichcanberepeatedatregular10minuteintervals(upto5times)

withoutcompromisingrecovery.

Table11:Detomidineandketamineequineanaesthesia(IV):Premedicationand

inductionofanaesthesia

Weightofhorse(kg) 50 100 150 200 250 300 400 500 600

Detomidine(10mg/ml)

dose(ml)* 0.100.200.300.400.500.600.80 1.00 1.20

Wait5minutes

Ketamine(100mg/ml)

dose(ml)** 1.102.203.304.405.506.608.8011.0013.20

*basedonadoserateof20µgdetomidine/kgbodyweight

**basedonadoserateof2.2mgketamine/kgbodyweight

Table12:Detomidineandketamineequineanaesthesia(IV):Maintenance(top-

up)doseat10minuteintervals

Weightofhorse(kg) 50 100 150 200 250 300 400 500 600

Detomidine(10mg/ml)

dose(ml)* 0.050.100.150.200.250.300.400.500.60

Ketamine(100mg/ml)

dose(ml)** 0.551.101.652.202.753.304.405.506.60

*basedonadoserateof10µgdetomidine/kgbodyweight

**basedonadoserateof1.1mgketamine/kgbodyweight

Romifidine/ketamine:

Romifidineshouldbeadministeredbyintravenousinjectionatadoserateof100µg/kg.

Thehorseshouldappearsedatedbyfivetotenminutespostinjection.Atthisstage

ketamineshouldbeadministeredatadoserateof2.2mg/kg(correspondingto2.2

ml/100kg)asanintravenousbolus.Sedationshouldbeapparentbeforetheinductionof

anaesthesia.

Maintenanceofsurgicalanaesthesia:

Shoulditbecomenecessarytoprolonganaesthesia,eitherofthefollowingregimesmay

beused:

a)Thiopentalsodium

Thiopentalsodiummaybeadministeredintravenouslyinbolusesof2.5mg/kgwhen

signsofreturningconsciousnessappear.Thiscanberepeatedupto3timesafter

induction.Totaldosesgreaterthanthismayreducethequalityofrecovery.Thehorse

maybeataxicifencouragedtostandprematurelyandsoshouldbelefttostandinits

owntime.

b)Romifidine/ketamine

Dependingondepthanddurationofanaesthesiarequired,administerromifidine

intravenouslywithinthedoserangeof25-50µg/kgbodyweight,i.e.¼-½theinitial

premedicationdosefollowedimmediatelybyketamineintravenouslyatadoserateof

1.1mg/kgbodyweight,i.e.½theinitialinductiondose).Eachtop-uplastsapproximately

8-10minutesandcanberepeatedatregular8-10minuteintervals(upto5times)

withoutcompromisingrecovery.

Issued:July2013

AN.02141/2011

Page11of13

Table13:Romifidineandketamineequineanaesthesia(IV):Premedicationand

inductionofanaesthesia

Weightofhorse(kg) 50 100 150 200 250 300 400 500 600

Romifidine(10mg/ml)

dose(ml)* 0.501.001.502.002.503.004.00 5.00 6.00

Wait5-10minutes

Ketamine(100mg/ml)

dose(ml)** 1.102.203.304.405.506.608.8011.0013.20

*basedonadoserateof100µgdetomidine/kgbodyweight

**basedonadoserateof2.2mgketamine/kgbodyweight

Table14:Romifidineandketamineequineanaesthesia(IV):Maintenance(top-

up)doseat8-10minuteintervals

Weightofhorse(kg) 50 100 150 200 250 300 400 500 600

Romifidine(10mg/ml)

dose(ml)* 0.250.500.751.001.251.502.002.503.00

Ketamine(100mg/ml)

dose(ml)** 0.551.101.652.202.753.304.405.506.60

*basedonadoserateof50µgromifidine/kgbodyweight

**basedonadoserateof1.1mgketamine/kgbodyweight

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Inexcessivedoses,significantrespiratorydepressionmayoccur.Ifnecessary,suitable

artificialaidstomaintainventilationandcardiacoutputshouldbeuseduntilsufficient

detoxificationhastakenplacetoenableareturntoadequatespontaneousventilation

andcardiacactivity.Pharmacologicalcardiacstimulantsarenotrecommended,unless

noothersupportivemeasuresareavailable.

4.11Withdrawalperiod(s)

Horse

Meatandoffal:1day

Milk:1day

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:dissociativeanaesthetic,ATCvetcode:QN01AX03

5.1.Pharmacodynamicproperties

Ketamineisadissociativeanaestheticagent.Ketamineinducesastateofcatalepsy

withamnesiaandanalgesia;muscletoneismaintainedincludingthepharyngealand

laryngealreflexes.Theheartrate,bloodpressureandcardiacoutputareincreased;

respiratorydepressionisnotanoticeablefeature.Allthesecharacteristicsmaybe

modifiediftheproductisusedincombinationwithotheragents.

5.2.Pharmacokineticparticulars

Issued:July2013

AN.02141/2011

Page12of13

Ketamineundergoesextensivehepaticbiotransformationindogs,horsesandprimates.

Somehepaticmetabolismoccursincats,butnormallythemajorityofthedrugis

excretedviathekidney.Recoveryofketamineafterintravenousbolusisbyrapid

redistributionfromtheCNStoothertissues,primarilyfat,lung,liverandkidney.

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Chlorocresol

Sodiumhydroxide(forpHadjustment)

Hydrochloricacid(forpHadjustment)

Waterforinjections

6.2Incompatibilities

Theproductmustnotbemixedwithotherveterinarymedicinalproducts,withthe

exceptionoftheinfusionfluids0.9%sodiumchloride,Ringerssolutionandlactated

Ringerssolution.

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:3years

Shelf-lifeafterfirstopeningtheimmediatepackaging:28days

6.4.Specialprecautionsforstorage

Thisveterinarymedicinalproductdoesnotrequireanyspecialstorageconditions.

6.5Natureandcompositionofimmediatepackaging

ClearcolourlesstypeIglassvialswithbromobutylrubberstoppersandaluminiumcaps

filledwith5ml,10ml,20ml,25ml,30mland50ml.

1vialinacardboardbox

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinary

medicinalproductsshouldbedisposedofinaccordancewithlocalrequirements.

7. MARKETINGAUTHORISATIONHOLDER

EurovetAnimalHealthB.V.

Handelsweg25,5531AEBladel,TheNetherlands

8. MARKETINGAUTHORISATIONNUMBER

Vm16849/4048

Issued:July2013

AN.02141/2011

Page13of13

9. DATEOFFIRSTAUTHORISATION

08July2013

10 DATEOFREVISIONOFTHETEXT

July2013

Approved: 08/07/2013

28-11-2018

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Prenoxad 1 mg/mL solution for injection (naloxone hydrochloride)

Update - medicine shortage

Therapeutic Goods Administration - Australia

13-7-2018

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira, Inc., a Pfizer company, is voluntarily recalling 8 lots of Hospira’s Daptomycin for Injection 500 mg, Lyophilized Powder For Solution, Single Dose Vial (NDC 0409-0106-01) to the Hospital/Retail level. The product is being recalled due to adverse event reports indicative of infusion reactions.

FDA - U.S. Food and Drug Administration

15-6-2018

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

At least 43 patient reported adverse event after receiving eye injections of Guardian’s Pharmacy Services compounded triamcinolone-moxifloxacin product during cataract surgery. The patients reportedly experienced various symptoms, including vision impairment, poor night vision, loss of color perception, and significant reductions in best-corrected visual acuity and visual fields. FDA identified multiple substances in Guardian’s product, including poloxamer 407 and poloxamer 407 degradants. FDA prepared i...

FDA - U.S. Food and Drug Administration

4-6-2018

Hospira Issues a Voluntary Nationwide Recall for Two Lots of Naloxone Hydrochloride Injection, USP, in the Carpuject™ Syringe System due to the Potential Presence of Particulate Matter

Hospira Issues a Voluntary Nationwide Recall for Two Lots of Naloxone Hydrochloride Injection, USP, in the Carpuject™ Syringe System due to the Potential Presence of Particulate Matter

Hospira, Inc., a Pfizer company, is voluntarily recalling lots 72680LL and 76510LL of Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL, Carpuject Single-use cartridge syringe system (NDC 0409-1782-69), to the hospital/institution level due to the potential presence of embedded and loose particulate matter on the syringe plunger.

FDA - U.S. Food and Drug Administration

4-6-2018

Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL in the Carpuject™ Single-use Cartridge Syringe System   by Hospira: Recall - Due to the Potential Presence of Particulate Matter

Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL in the Carpuject™ Single-use Cartridge Syringe System by Hospira: Recall - Due to the Potential Presence of Particulate Matter

The patient has a low likelihood of experiencing adverse events ranging from local irritation, allergic reactions, phlebitis, end-organ granuloma, tissue ischemia, pulmonary emboli, pulmonary dysfunction, pulmonary infarction, and toxicity.

FDA - U.S. Food and Drug Administration

5-7-2018

Scientific guideline:  Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

Scientific guideline: Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

This document provides product-specific guidance on the demonstration of the bioequivalence of pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml.

Europe - EMA - European Medicines Agency

29-5-2018

EU/3/18/2017 (Spedding Research Solutions SAS)

EU/3/18/2017 (Spedding Research Solutions SAS)

EU/3/18/2017 (Active substance: Ambroxol hydrochloride) - Orphan designation - Commission Decision (2018)3384 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/236/17

Europe -DG Health and Food Safety